Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index; 12 of the 30 sources its claims cite were checked for support.

An Autologous Macrophage‐Based Phenotypic Transformation‐Collagen Degradation System Treating Advanced Liver Fibrosis

Open access
Duan, Bo‐Wen, Liu, Yan‐Jun, Li, Xue‐Na, Han, Meng‐Meng, Yu, Hao‐Yuan, Hong, He‐Yuan, Zhang, Ling‐Feng, Xing, Lei, Jiang, Hu‐Lin · 2024 · Advanced Science

Abstract

In advanced liver fibrosis (LF), macrophages maintain the inflammatory environment in the liver and accelerate LF deterioration by secreting proinflammatory cytokines. However, there is still no effective strategy to regulate macrophages because of the difficulty and complexity of macrophage inflammatory phenotypic modulation and the insufficient therapeutic efficacy caused by the extracellular matrix (ECM) barrier. Here, AC73 and siUSP1 dual drug‐loaded lipid nanoparticle is designed to carry milk fat globule epidermal growth factor 8 (MFG‐E8) (named MUA/Y) to effectively inhibit macrophage proinflammatory signals and degrade the ECM barrier. MFG‐E8 is released in response to the high reactive oxygen species (ROS) environment in LF, transforming macrophages from a proinflammatory (M1) to an anti‐inflammatory (M2) phenotype and inducing macrophages to phagocytose collagen. Collagen ablation increases AC73 and siUSP1 accumulation in hepatic stellate cells (HSCs) and inhibits HSCs overactivation. Interestingly, complete resolution of liver inflammation, significant collagen degradation, and HSCs deactivation are observed in methionine choline deficiency (MCD) and CCl 4 models after tail vein injection of MUA/Y. Overall, this work reveals a macrophage‐focused regulatory treatment strategy to eliminate LF progression at the source, providing a new perspective for the clinical treatment of advanced LF.

Overview

CoChat Summary

TL;DR

This paper presents MUA/Y, a dual-drug lipid nanoparticle coated with MFG-E8, to treat advanced liver fibrosis by both reprogramming macrophages and breaking down the collagen-rich ECM barrier. In mouse MCD and CCl4 fibrosis models, the system reduced inflammation, collagen deposition, and hepatic stellate cell (HSC) activation, with the authors stating collagen content was not significantly different from the normal group after treatment.

Key findings

  • MFG-E8 shifted macrophages from a proinflammatory to an anti-inflammatory state: in LPS-primed RAW264.7 cells, M1 macrophages decreased from 87.2% to 54.9% and M2 macrophages increased to 38.3% after MFG-E8 administration.
  • In primary liver macrophages from MCD-fed mice, MFG-E8 induced phenotypic transformation in only 26.5% of macrophages at 5 weeks and 16.1% at 9 weeks, showing reduced responsiveness in advanced fibrosis.
  • The final formulation MUA/Y had a particle size of about 175 nm and strong stability in PBS and 10% FBS; the AC73 release was about 46% at 72 h at pH 7.4 and about 65% at 72 h at pH 5.0.
  • In the MCD model, MUA/Y reduced hydroxyproline content, collagen deposition, and inflammatory cytokines back to normal levels, and the authors report no significant difference in collagen content from the normal group after treatment; similar antifibrotic effects were reported in the CCl4 model.

Methods

  • The study designed an autologous macrophage-based lipid nanoparticle system, MUA/Y, carrying AC73 and siUSP1, with MFG-E8 adsorbed on the surface; MFG-E8 was intended to release in high-ROS fibrotic regions.
  • In vitro work used RAW264.7 macrophages, HSC-T6 hepatic stellate cells, and coculture / transwell-style assays to test macrophage phenotypic switching, collagen phagocytosis, HSC activation, uptake, endosomal escape, and cytotoxicity.
  • In vivo efficacy was tested by tail-vein injection in two advanced fibrosis mouse models: MCD-fed C57BL/6J mice for 63 days and a CCl4-induced model; outcomes included histology, hydroxyproline, inflammatory cytokines, transaminases, and marker expression.

Limitations

  • The paper itself states that “the difficulty and complexity of macrophage inflammatory phenotypic modulation” and the “insufficient therapeutic efficacy caused by the extracellular matrix barrier” are major problems; these are presented as the motivation for the work rather than as study limitations.
  • The text makes evident that much of the evidence is preclinical and relies on cell experiments and mouse models only; no human data are described.
  • The text also shows that phenotypic conversion by MFG-E8 in primary macrophages was limited in advanced fibrosis (16.1% at 9 weeks), indicating incomplete responsiveness of diseased tissue.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1002/advs.202306899

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Scheme 1 Schematic illustration of the MUA/Y lipid nanoparticles. A)The formation of A/Y and MUA/Y lipid nanoparticles. B) Under high ROS conditions in vivo, i) MFG‐E8 was released ii) and subsequently induced macrophage phenotype transformation and phagocytosis of collagen, iii) then AC73 and siUSP‐1 inhibited HSCs activation and proliferation, thereby exerting an anti‐LF effect.
Scheme 1 Schematic illustration of the MUA/Y lipid nanoparticles. A)The formation of A/Y and MUA/Y lipid nanoparticles. B) Under high ROS conditions in vivo, i) MFG‐E8 was released ii) and subsequently induced macrophage phenotype transformation and phagocytosis of collagen, iii) then AC73 and siUSP‐1 inhibited HSCs activation and proliferation, thereby exerting an anti‐LF effect.CC BY · PubMed Central
Figure 1 Macrophages influence the progression of LF. A) The process of M1 and M2 macrophages induced by LPS and IL‐4. B‐C) Detection of iNOS and CD206 expression in M1 and M2 macrophages by flow cytometry. D) CLSM images of immunofluorescence staining of α‐SMA of HSC after activated by M1 macrophage supernatant. Scale bar = 20 µm. E) Western blot analysis of α‐SMA in HSCs induced by M1 macrophages supernatant. The expression of collagen I, α‐SMA, and vimentin were normalized to the expression of β‐actin (n = 3). F) The process of M1 macrophage phenotype reversion by MFG‐E8. G) Detection of iNOS and CD206 expression by flow cytometry after incubation with MFG‐E8. Data represented mean ± SD, *p < 0.05, ***p < 0.001.
Figure 1 Macrophages influence the progression of LF. A) The process of M1 and M2 macrophages induced by LPS and IL‐4. B‐C) Detection of iNOS and CD206 expression in M1 and M2 macrophages by flow cytometry. D) CLSM images of immunofluorescence staining of α‐SMA of HSC after activated by M1 macrophage supernatant. Scale bar = 20 µm. E) Western blot analysis of α‐SMA in HSCs induced by M1 macrophages supernatant. The expression of collagen I, α‐SMA, and vimentin were normalized to the expression of β‐actin (n = 3). F) The process of M1 macrophage phenotype reversion by MFG‐E8. G) Detection of iNOS and CD206 expression by flow cytometry after incubation with MFG‐E8. Data represented mean ± SD, *p < 0.05, ***p < 0.001.CC BY · PubMed Central
Figure 2 Expression of CXCL1 and CD147 in activated HSCs. A) CLSM images of CXCL1 (red) and α‐SMA (green) immunostaining in activated and quiet HSCs. Scale bars = 10 µm. B) Detection of CXCL1 and SMA expression in activated HSCs by flow cytometry. C) Western blot analysis of USP1, CXCL1, and α‐SMA in HSCs after undergoing different treatments. (n = 3, mean ± SD). D) CLSM images of CD147 (red) and collagen I (green) immunostaining in activated and quiet HSCs. Scale bars = 10 µm. E) CLSM images of CXCL1 (red) and CD147 (green) immunostaining in HSCs after being stimulated by TGF‐β. Scale bars = 10 µm. F,G) Detection of CXCL1/collagen I and CD147/CXCL1 co‐expression in activated HSCs by flow cytometry. H) Western blot analysis of CD147, CXCL1, and α‐SMA in HSCs after undergoing different treatments. The expression of CD147, CXCL1, and α‐SMA were normalized to the expression of β‐actin. (n = 3). Data represented mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 2 Expression of CXCL1 and CD147 in activated HSCs. A) CLSM images of CXCL1 (red) and α‐SMA (green) immunostaining in activated and quiet HSCs. Scale bars = 10 µm. B) Detection of CXCL1 and SMA expression in activated HSCs by flow cytometry. C) Western blot analysis of USP1, CXCL1, and α‐SMA in HSCs after undergoing different treatments. (n = 3, mean ± SD). D) CLSM images of CD147 (red) and collagen I (green) immunostaining in activated and quiet HSCs. Scale bars = 10 µm. E) CLSM images of CXCL1 (red) and CD147 (green) immunostaining in HSCs after being stimulated by TGF‐β. Scale bars = 10 µm. F,G) Detection of CXCL1/collagen I and CD147/CXCL1 co‐expression in activated HSCs by flow cytometry. H) Western blot analysis of CD147, CXCL1, and α‐SMA in HSCs after undergoing different treatments. The expression of CD147, CXCL1, and α‐SMA were normalized to the expression of β‐actin. (n = 3). Data represented mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001.CC BY · PubMed Central
Figure 3 Characterization of MUA/Y lipid nanoparticles. A) The illustration on the formation of A/Y and MUA/Y. B) The DLE% and EE% of AC73 in MUA/Y lipid nanoparticles at different drug/phospholipid ratios (n = 3). C) The fluorescent spectrum of FITC excited RhB treated with RhB‐MFG‐E8@FITC/Y lipid nanoparticles. D) The structural changes of MFG‐E8 were verified by circular dichroism (CD). E) Size distribution and TEM result of MUA/Y. TEM Scale bar = 500 nm. F) In vitro colloidal stability of MUA/Y in water, PBS, and FBS for 72 h (n = 3). G) Time‐dependent AC73 release of free AC73 and MUA/Y in PBS at pH 5.0, and 7.4 (n = 3). H) ROS response ability of MUA/Y lipid nanoparticles. Scale bars = 100 µm. Data were represented as mean ± SD.
Figure 3 Characterization of MUA/Y lipid nanoparticles. A) The illustration on the formation of A/Y and MUA/Y. B) The DLE% and EE% of AC73 in MUA/Y lipid nanoparticles at different drug/phospholipid ratios (n = 3). C) The fluorescent spectrum of FITC excited RhB treated with RhB‐MFG‐E8@FITC/Y lipid nanoparticles. D) The structural changes of MFG‐E8 were verified by circular dichroism (CD). E) Size distribution and TEM result of MUA/Y. TEM Scale bar = 500 nm. F) In vitro colloidal stability of MUA/Y in water, PBS, and FBS for 72 h (n = 3). G) Time‐dependent AC73 release of free AC73 and MUA/Y in PBS at pH 5.0, and 7.4 (n = 3). H) ROS response ability of MUA/Y lipid nanoparticles. Scale bars = 100 µm. Data were represented as mean ± SD.CC BY · PubMed Central
Figure 4 Characterization of collagen phagocytosis, cellular uptake, and endosome escape of MUA/Y lipid nanoparticles. A) The process of collagen phagocytosis mediates by MFG‐E8. B) The process of MFG‐E8 mediated macrophages ablate collagen. C) Fluorescence intensity in HSCs detected by fluorescence microscopy. Scale bars = 100 µm. D) FITC‐modified collagen was endocytosed by RAW264.7. The image was captured by CLSM. Scale bars = 10 µm. E) The process of MUA/Y endocytosed escape in HSCs. F) CLSM images of cellular uptake of free C6, C6/Y, and MUC6/Y under 2 and 4 h. Scale bars = 20 µm. G) Transfection efficiency of siLuc loaded lipid nanoparticles detected by fluorescence microscopy. Scale bars = 100 µm. H) Semiquantitative analyze of the Luc positive area of fluorescent cells. (n = 3). Data represented mean ± SD. ns: no significant difference, *p < 0.05, ***p < 0.001.
Figure 4 Characterization of collagen phagocytosis, cellular uptake, and endosome escape of MUA/Y lipid nanoparticles. A) The process of collagen phagocytosis mediates by MFG‐E8. B) The process of MFG‐E8 mediated macrophages ablate collagen. C) Fluorescence intensity in HSCs detected by fluorescence microscopy. Scale bars = 100 µm. D) FITC‐modified collagen was endocytosed by RAW264.7. The image was captured by CLSM. Scale bars = 10 µm. E) The process of MUA/Y endocytosed escape in HSCs. F) CLSM images of cellular uptake of free C6, C6/Y, and MUC6/Y under 2 and 4 h. Scale bars = 20 µm. G) Transfection efficiency of siLuc loaded lipid nanoparticles detected by fluorescence microscopy. Scale bars = 100 µm. H) Semiquantitative analyze of the Luc positive area of fluorescent cells. (n = 3). Data represented mean ± SD. ns: no significant difference, *p < 0.05, ***p < 0.001.CC BY · PubMed Central
Figure 5 Mechanisms of MUA/Y lipid nanoparticles in HSCs. A) Mechanisms of HSCs activation and recovery after treatment. B) The expression of CXCL1, CD147, Sp‐1, Erk1/2, Smad2, fibronectin, collagen I, and α‐SMA in HSCs undergoing different formulations. 1 means PBS group, 2 means TGF group, 3 means free AC73 group, 4 means siUSP1/Y, 5 means AC/Y, 6 means UA/Y. C–E) Densitometric quantification of western blotting results in each group. The expression of α‐SMA, collagen I and CD147 were normalized to β‐actin. (n = 3). F) Images for cell scratch assay of HSCs at 0 and 24 h (n = 3). Scale bars = 100 µm. G) Semi‐quantified of the scratch area of each group, the scratch area in each groups were normalized to PBS group (n = 3). H,I) CLSM images of CD147 (green)/CoI (red) and SMA (green)/CXCL1 (red) immunostaining in HSCs after treatment (n = 3). Scale bars = 100 µm. Data were represented as mean ± SD, ns: no significant difference, *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 5 Mechanisms of MUA/Y lipid nanoparticles in HSCs. A) Mechanisms of HSCs activation and recovery after treatment. B) The expression of CXCL1, CD147, Sp‐1, Erk1/2, Smad2, fibronectin, collagen I, and α‐SMA in HSCs undergoing different formulations. 1 means PBS group, 2 means TGF group, 3 means free AC73 group, 4 means siUSP1/Y, 5 means AC/Y, 6 means UA/Y. C–E) Densitometric quantification of western blotting results in each group. The expression of α‐SMA, collagen I and CD147 were normalized to β‐actin. (n = 3). F) Images for cell scratch assay of HSCs at 0 and 24 h (n = 3). Scale bars = 100 µm. G) Semi‐quantified of the scratch area of each group, the scratch area in each groups were normalized to PBS group (n = 3). H,I) CLSM images of CD147 (green)/CoI (red) and SMA (green)/CXCL1 (red) immunostaining in HSCs after treatment (n = 3). Scale bars = 100 µm. Data were represented as mean ± SD, ns: no significant difference, *p < 0.05, **p < 0.01, ***p < 0.001.CC BY · PubMed Central
Figure 6 Biodistribution and Intrahepatic distribution of MUA/Y lipid nanoparticles after intravenous injection. Mice received DIR‐loaded liposomes and free DiR administration 72 h after the last CCl4 injection. A) Schedule of the establishment of the mice LF model. B) Images of DiR tissue distribution in fibrotic mice in different groups at the indicated time points (n = 3) and quantities analysis of fluorescence intensity. C) Images of DiR distribution in main organ in different groups at the indicated time points (n = 3) and quantities analysis of fluorescence intensity. D) Analysis of the intrahepatic distribution of the AC73 (DiI) in fibrotic liver. Scale bars = 100 µm.
Figure 6 Biodistribution and Intrahepatic distribution of MUA/Y lipid nanoparticles after intravenous injection. Mice received DIR‐loaded liposomes and free DiR administration 72 h after the last CCl4 injection. A) Schedule of the establishment of the mice LF model. B) Images of DiR tissue distribution in fibrotic mice in different groups at the indicated time points (n = 3) and quantities analysis of fluorescence intensity. C) Images of DiR distribution in main organ in different groups at the indicated time points (n = 3) and quantities analysis of fluorescence intensity. D) Analysis of the intrahepatic distribution of the AC73 (DiI) in fibrotic liver. Scale bars = 100 µm.CC BY · PubMed Central
Figure 7 MUA/Y effectively inhibited the progression of MCD‐induced LF. A) Establishment and treatment strategy of advanced LF model. B) Representative images of Sirius red, α‐SMA, CD147 immunohistochemistry, and iNOS/CD206 immunofluorescence stained liver sections, scale bars = 100 µm. C,D) TGF‐β, IL‐1β, IL‐6, and TNF‐α levels in serum and liver tissue (n = 3). E) The hydroxyproline (Hyp) level in the liver of mice in each treatment group (n = 3). The group sequence was similar to Figure 7B. F) The expression level of Collagen I, α‐SMA, p‐Erk, CXCL1, CD147, USP1, Sp‐1 undergoing different formulation and the Semi‐quantitative analysis of Collagen I, α‐SMA, p‐Erk. 1 means normal, 2 means fibrosis group, 3 means free AC73 group, 4 means free MFG group, 5 means U/Y group, 6 means A/Y group and 7 means MUA/Y. The expression of α‐SMA, collagen I and p‐Erk were normalized to the expression of β‐actin. Data were represented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ns: no significant difference.
Figure 7 MUA/Y effectively inhibited the progression of MCD‐induced LF. A) Establishment and treatment strategy of advanced LF model. B) Representative images of Sirius red, α‐SMA, CD147 immunohistochemistry, and iNOS/CD206 immunofluorescence stained liver sections, scale bars = 100 µm. C,D) TGF‐β, IL‐1β, IL‐6, and TNF‐α levels in serum and liver tissue (n = 3). E) The hydroxyproline (Hyp) level in the liver of mice in each treatment group (n = 3). The group sequence was similar to Figure 7B. F) The expression level of Collagen I, α‐SMA, p‐Erk, CXCL1, CD147, USP1, Sp‐1 undergoing different formulation and the Semi‐quantitative analysis of Collagen I, α‐SMA, p‐Erk. 1 means normal, 2 means fibrosis group, 3 means free AC73 group, 4 means free MFG group, 5 means U/Y group, 6 means A/Y group and 7 means MUA/Y. The expression of α‐SMA, collagen I and p‐Erk were normalized to the expression of β‐actin. Data were represented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ns: no significant difference.CC BY · PubMed Central

Verification

Claims the paper makes

7 Valid · 4 Not valid · 12 Not checked · 130 Own results and interpretations

74 more claims

Create a free account to see all 153 claims and to verify the 4 references still open.

See all claims — free account
  • Probably not a substantial claim. 6
  • It may state two separate claims as one. 70
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 39 references

Research works printed but not linked: 1

  1. Prakash Ramachandrana A. P., 2012, Proc. Natl. Acad. Sci. USA, 109

Cited by

See all 38

Metadata

Authors
Duan, B., Liu, Y., Li, X., Han, M., Yu, H., Hong, H., Zhang, L., Xing, L., & Jiang, H.
Affiliations
  • China Pharmaceutical University (CN)
  • State Key Laboratory of Natural Medicines China Pharmaceutical University Nanjing 210009 China
Corresponding author
Jiang, Hu‐Lin
Venue
Advanced Science
Publisher
Wiley
Published
2023-12-08
Volume
11
Issue
7
Pages
e2306899-e2306899
ISSN
2198-3844 (ISSN-L)
OpenAlex
W4389476564
Cited by
38
References
39
Citations by year
2026: 10 · 2025: 17 · 2024: 10 · 2023: 1
FWCI
6.36
Type
journal article
Language
en
Open access
Locations
  • Advanced Science (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Key Research and Development Program of China (2022YFE0198400)
  • National Natural Science Foundation of China (82020108029, 82073398)
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Keywords
advanced liver fibrosis, collagen degradation, hepatic stellate cell activation, MFG-E8, reactive oxygen species-responsive release, liver inflammation
MeSH terms
Collagen, Humans, Liver Cirrhosis, Macrophages, Phenotype

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An Autologous Macrophage‐Based Phenotypic Transformation‐Collagen Degradation System Treating Advanced Liver Fibrosis. https://app.cochat.ai/papers/10.1002/advs.202306899
The paper
Duan, B., Liu, Y., Li, X., Han, M., Yu, H., Hong, H., Zhang, L., Xing, L., & Jiang, H. (2024). An Autologous Macrophage‐Based Phenotypic Transformation‐Collagen Degradation System Treating Advanced Liver Fibrosis. Advanced Science. https://doi.org/10.1002/advs.202306899

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.